JAMA Intern Med:HIV阳性结核病患者每日抗结核药物治疗方案效果更佳

2018-03-12 zhangfan MedSci原创

研究认为,对于HIV阳性的结核病患者,每日抗结核治疗的效果优于每周3次给药方案,且不易导致利福平耐药

对于正在接受抗病毒药物治疗的HIV阳性肺结核患者,每周3次抗结核药物治疗是标准治疗方案。近日研究人员考察了增加药物治疗频率对患者的治疗效果、不良事件以及耐药性的影响。

新近确诊的肺结核阳性HIV感染患者参与研究,随机接受每日、间隔每日以及隔日抗结核治疗,患者每月进行临床及痰微生物检查,至随机分组后18个月。研究的主要终点是肺结核治疗响应,即治疗后结核分枝杆菌检测阴性,治疗无响应定义为治疗失败、中断、死亡和毒副作用。

331名患者参与研究,男性占76%,平均年龄39岁,平均HIV病毒当量为4.9 log10拷贝,平均CD4细胞计数为138/μL。每日、间隔每日以及隔日抗结核治疗组治疗响应率分别为91%、80%以及77%。隔日治疗组患者中4人出现利福平耐药。研究过程中18人死亡,18人退出。每日、间隔每日以及隔日抗结核治疗组分别有6、4、6人出现疾病结核病复发。

研究认为,对于HIV阳性的结核病患者,每日抗结核治疗的效果优于每周3次给药方案,且不易导致利福平耐药。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905045, encodeId=16a8190504537, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Aug 13 13:39:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746216, encodeId=3fd81e46216ba, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Mar 16 01:39:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668577, encodeId=b8bd16685e701, content=<a href='/topic/show?id=988c556181c' target=_blank style='color:#2F92EE;'>#抗结核药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55618, encryptionId=988c556181c, topicName=抗结核药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=504a26353164, createdName=wincls, createdTime=Tue May 29 21:39:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967409, encodeId=8c93196e4098d, content=<a href='/topic/show?id=65995561e43' target=_blank style='color:#2F92EE;'>#抗结核药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55617, encryptionId=65995561e43, topicName=抗结核药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Sep 30 01:39:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254147, encodeId=0155125414eb0, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509895, encodeId=eb4015098956c, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575307, encodeId=74a215e5307b7, content=<a href='/topic/show?id=28138930d2' target=_blank style='color:#2F92EE;'>#HIV阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8930, encryptionId=28138930d2, topicName=HIV阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e16086652, createdName=zxl734, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608629, encodeId=f5011608629ff, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295683, encodeId=0aa32956838c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Mar 13 05:54:59 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295510, encodeId=6fe529551091, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 12 11:53:11 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1905045, encodeId=16a8190504537, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Aug 13 13:39:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746216, encodeId=3fd81e46216ba, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Mar 16 01:39:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668577, encodeId=b8bd16685e701, content=<a href='/topic/show?id=988c556181c' target=_blank style='color:#2F92EE;'>#抗结核药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55618, encryptionId=988c556181c, topicName=抗结核药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=504a26353164, createdName=wincls, createdTime=Tue May 29 21:39:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967409, encodeId=8c93196e4098d, content=<a href='/topic/show?id=65995561e43' target=_blank style='color:#2F92EE;'>#抗结核药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55617, encryptionId=65995561e43, topicName=抗结核药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Sep 30 01:39:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254147, encodeId=0155125414eb0, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509895, encodeId=eb4015098956c, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575307, encodeId=74a215e5307b7, content=<a href='/topic/show?id=28138930d2' target=_blank style='color:#2F92EE;'>#HIV阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8930, encryptionId=28138930d2, topicName=HIV阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e16086652, createdName=zxl734, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608629, encodeId=f5011608629ff, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295683, encodeId=0aa32956838c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Mar 13 05:54:59 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295510, encodeId=6fe529551091, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 12 11:53:11 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1905045, encodeId=16a8190504537, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Aug 13 13:39:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746216, encodeId=3fd81e46216ba, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Mar 16 01:39:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668577, encodeId=b8bd16685e701, content=<a href='/topic/show?id=988c556181c' target=_blank style='color:#2F92EE;'>#抗结核药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55618, encryptionId=988c556181c, topicName=抗结核药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=504a26353164, createdName=wincls, createdTime=Tue May 29 21:39:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967409, encodeId=8c93196e4098d, content=<a href='/topic/show?id=65995561e43' target=_blank style='color:#2F92EE;'>#抗结核药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55617, encryptionId=65995561e43, topicName=抗结核药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Sep 30 01:39:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254147, encodeId=0155125414eb0, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509895, encodeId=eb4015098956c, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575307, encodeId=74a215e5307b7, content=<a href='/topic/show?id=28138930d2' target=_blank style='color:#2F92EE;'>#HIV阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8930, encryptionId=28138930d2, topicName=HIV阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e16086652, createdName=zxl734, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608629, encodeId=f5011608629ff, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295683, encodeId=0aa32956838c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Mar 13 05:54:59 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295510, encodeId=6fe529551091, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 12 11:53:11 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1905045, encodeId=16a8190504537, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Aug 13 13:39:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746216, encodeId=3fd81e46216ba, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Mar 16 01:39:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668577, encodeId=b8bd16685e701, content=<a href='/topic/show?id=988c556181c' target=_blank style='color:#2F92EE;'>#抗结核药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55618, encryptionId=988c556181c, topicName=抗结核药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=504a26353164, createdName=wincls, createdTime=Tue May 29 21:39:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967409, encodeId=8c93196e4098d, content=<a href='/topic/show?id=65995561e43' target=_blank style='color:#2F92EE;'>#抗结核药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55617, encryptionId=65995561e43, topicName=抗结核药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Sep 30 01:39:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254147, encodeId=0155125414eb0, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509895, encodeId=eb4015098956c, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575307, encodeId=74a215e5307b7, content=<a href='/topic/show?id=28138930d2' target=_blank style='color:#2F92EE;'>#HIV阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8930, encryptionId=28138930d2, topicName=HIV阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e16086652, createdName=zxl734, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608629, encodeId=f5011608629ff, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295683, encodeId=0aa32956838c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Mar 13 05:54:59 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295510, encodeId=6fe529551091, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 12 11:53:11 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1905045, encodeId=16a8190504537, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Aug 13 13:39:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746216, encodeId=3fd81e46216ba, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Mar 16 01:39:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668577, encodeId=b8bd16685e701, content=<a href='/topic/show?id=988c556181c' target=_blank style='color:#2F92EE;'>#抗结核药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55618, encryptionId=988c556181c, topicName=抗结核药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=504a26353164, createdName=wincls, createdTime=Tue May 29 21:39:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967409, encodeId=8c93196e4098d, content=<a href='/topic/show?id=65995561e43' target=_blank style='color:#2F92EE;'>#抗结核药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55617, encryptionId=65995561e43, topicName=抗结核药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Sep 30 01:39:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254147, encodeId=0155125414eb0, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509895, encodeId=eb4015098956c, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575307, encodeId=74a215e5307b7, content=<a href='/topic/show?id=28138930d2' target=_blank style='color:#2F92EE;'>#HIV阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8930, encryptionId=28138930d2, topicName=HIV阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e16086652, createdName=zxl734, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608629, encodeId=f5011608629ff, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295683, encodeId=0aa32956838c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Mar 13 05:54:59 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295510, encodeId=6fe529551091, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 12 11:53:11 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1905045, encodeId=16a8190504537, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Aug 13 13:39:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746216, encodeId=3fd81e46216ba, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Mar 16 01:39:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668577, encodeId=b8bd16685e701, content=<a href='/topic/show?id=988c556181c' target=_blank style='color:#2F92EE;'>#抗结核药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55618, encryptionId=988c556181c, topicName=抗结核药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=504a26353164, createdName=wincls, createdTime=Tue May 29 21:39:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967409, encodeId=8c93196e4098d, content=<a href='/topic/show?id=65995561e43' target=_blank style='color:#2F92EE;'>#抗结核药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55617, encryptionId=65995561e43, topicName=抗结核药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Sep 30 01:39:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254147, encodeId=0155125414eb0, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509895, encodeId=eb4015098956c, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575307, encodeId=74a215e5307b7, content=<a href='/topic/show?id=28138930d2' target=_blank style='color:#2F92EE;'>#HIV阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8930, encryptionId=28138930d2, topicName=HIV阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e16086652, createdName=zxl734, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608629, encodeId=f5011608629ff, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295683, encodeId=0aa32956838c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Mar 13 05:54:59 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295510, encodeId=6fe529551091, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 12 11:53:11 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
    2018-03-14 wgx309
  7. [GetPortalCommentsPageByObjectIdResponse(id=1905045, encodeId=16a8190504537, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Aug 13 13:39:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746216, encodeId=3fd81e46216ba, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Mar 16 01:39:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668577, encodeId=b8bd16685e701, content=<a href='/topic/show?id=988c556181c' target=_blank style='color:#2F92EE;'>#抗结核药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55618, encryptionId=988c556181c, topicName=抗结核药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=504a26353164, createdName=wincls, createdTime=Tue May 29 21:39:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967409, encodeId=8c93196e4098d, content=<a href='/topic/show?id=65995561e43' target=_blank style='color:#2F92EE;'>#抗结核药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55617, encryptionId=65995561e43, topicName=抗结核药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Sep 30 01:39:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254147, encodeId=0155125414eb0, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509895, encodeId=eb4015098956c, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575307, encodeId=74a215e5307b7, content=<a href='/topic/show?id=28138930d2' target=_blank style='color:#2F92EE;'>#HIV阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8930, encryptionId=28138930d2, topicName=HIV阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e16086652, createdName=zxl734, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608629, encodeId=f5011608629ff, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295683, encodeId=0aa32956838c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Mar 13 05:54:59 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295510, encodeId=6fe529551091, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 12 11:53:11 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
    2018-03-14 zxl734
  8. [GetPortalCommentsPageByObjectIdResponse(id=1905045, encodeId=16a8190504537, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Aug 13 13:39:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746216, encodeId=3fd81e46216ba, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Mar 16 01:39:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668577, encodeId=b8bd16685e701, content=<a href='/topic/show?id=988c556181c' target=_blank style='color:#2F92EE;'>#抗结核药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55618, encryptionId=988c556181c, topicName=抗结核药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=504a26353164, createdName=wincls, createdTime=Tue May 29 21:39:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967409, encodeId=8c93196e4098d, content=<a href='/topic/show?id=65995561e43' target=_blank style='color:#2F92EE;'>#抗结核药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55617, encryptionId=65995561e43, topicName=抗结核药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Sep 30 01:39:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254147, encodeId=0155125414eb0, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509895, encodeId=eb4015098956c, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575307, encodeId=74a215e5307b7, content=<a href='/topic/show?id=28138930d2' target=_blank style='color:#2F92EE;'>#HIV阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8930, encryptionId=28138930d2, topicName=HIV阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e16086652, createdName=zxl734, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608629, encodeId=f5011608629ff, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295683, encodeId=0aa32956838c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Mar 13 05:54:59 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295510, encodeId=6fe529551091, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 12 11:53:11 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1905045, encodeId=16a8190504537, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Aug 13 13:39:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746216, encodeId=3fd81e46216ba, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Mar 16 01:39:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668577, encodeId=b8bd16685e701, content=<a href='/topic/show?id=988c556181c' target=_blank style='color:#2F92EE;'>#抗结核药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55618, encryptionId=988c556181c, topicName=抗结核药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=504a26353164, createdName=wincls, createdTime=Tue May 29 21:39:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967409, encodeId=8c93196e4098d, content=<a href='/topic/show?id=65995561e43' target=_blank style='color:#2F92EE;'>#抗结核药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55617, encryptionId=65995561e43, topicName=抗结核药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Sep 30 01:39:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254147, encodeId=0155125414eb0, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509895, encodeId=eb4015098956c, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575307, encodeId=74a215e5307b7, content=<a href='/topic/show?id=28138930d2' target=_blank style='color:#2F92EE;'>#HIV阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8930, encryptionId=28138930d2, topicName=HIV阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e16086652, createdName=zxl734, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608629, encodeId=f5011608629ff, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295683, encodeId=0aa32956838c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Mar 13 05:54:59 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295510, encodeId=6fe529551091, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 12 11:53:11 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
    2018-03-13 秀红

    学习了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1905045, encodeId=16a8190504537, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Mon Aug 13 13:39:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746216, encodeId=3fd81e46216ba, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf9935672064, createdName=木头人525, createdTime=Fri Mar 16 01:39:00 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668577, encodeId=b8bd16685e701, content=<a href='/topic/show?id=988c556181c' target=_blank style='color:#2F92EE;'>#抗结核药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55618, encryptionId=988c556181c, topicName=抗结核药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=504a26353164, createdName=wincls, createdTime=Tue May 29 21:39:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967409, encodeId=8c93196e4098d, content=<a href='/topic/show?id=65995561e43' target=_blank style='color:#2F92EE;'>#抗结核药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55617, encryptionId=65995561e43, topicName=抗结核药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Sep 30 01:39:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254147, encodeId=0155125414eb0, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509895, encodeId=eb4015098956c, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575307, encodeId=74a215e5307b7, content=<a href='/topic/show?id=28138930d2' target=_blank style='color:#2F92EE;'>#HIV阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8930, encryptionId=28138930d2, topicName=HIV阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e16086652, createdName=zxl734, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608629, encodeId=f5011608629ff, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 01:39:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295683, encodeId=0aa32956838c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue Mar 13 05:54:59 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295510, encodeId=6fe529551091, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 12 11:53:11 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
    2018-03-12 一个字-牛

    学习了谢谢分享

    0

相关资讯

ACIE:化学半合成法发现抗结核新型化合物

结核病(tuberculosis,TB)是世界第二大致死性感染疾病,近年来由于结核感染与艾滋感染的协同作用、全球人员的不断流动、不合格的公共卫生项目、耐药性及感染的持久性等原因,使开发新型抗结核药物的需求更为迫切。中国科学院微生物所张立新实验室使用带有绿色荧光蛋白(GFP)表达载体的牛型结核分支杆菌Mycobacterium bovis减毒株bacillus Calmette-Guérin,即BC

北京胸科医院观察:胸外二科刘志东:对抗结核和肿瘤的致胜法宝

从结核转战肿瘤,再到重新审视结核,北京胸科医院的胸外科团队肩上的担子从未放下过。能在两个领域都保持一流水平的才略,或许是当前胸外科应对胸部疾病的制胜关键。

NEJM:强化抗结核治疗不能提高成人结核性脑膜炎患者生存率

结核性脑膜炎往往是致命的。糖皮质激素进行早期抗结核治疗和辅助治疗可提高存活率,但近三分之一的该疾病患者仍然会死亡。研究人员假设,强化抗结核治疗会增强脑结核杆菌的杀灭,降低患者的死亡率。原始出处:A. Dorothee Heemskerk,Nguyen D. Bang,Nguyen T.H. Mai,et al.Intensified Antituberculosis Therapy in Adul

全球抗结核新药进中国 胸科医院患者首位体验

第一个抗结核新富马酸贝达喹啉终于来到中国结核病患者身边。

Am J Respir Crit Care Med:高剂量维生素D3能否助力抗结核治疗?

现有关于维生素D辅助治疗肺结核(PTB)的试验受到样本量小、剂量方案不足和受试者较高的基线维生素状态等多方面的限制。缺乏关于利用基因多态性分析维生素D通路对于维生素D补充应答影响的综合分析。2017年9月,发表在《Am J Respir Crit Care Med》的一项随机对照研究调查了高剂量维生素D3在抗结核治疗中的作用。